These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31548814)

  • 1. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
    Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
    Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
    Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
    Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma.
    Ulusakarya A; Teyar N; Karaboué A; Haydar M; Krimi S; Biondani P; Gumus Y; Chebib A; Almohamad W; Morère JF
    Medicine (Baltimore); 2019 Apr; 98(16):e15341. PubMed ID: 31008993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
    Kobayashi N; Omae K; Horita Y; Ueno H; Mizuno N; Uesugi K; Sudo K; Ozaka M; Hayashi H; Okano N; Kamei K; Yamaguchi A; Kobayashi S; Suzuki S; Ishihara S; Uchiyama T; Todaka A; Fukutomi A
    Pancreatology; 2020 Oct; 20(7):1519-1525. PubMed ID: 32972834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
    Chevalier H; Vienot A; Lièvre A; Edeline J; El Hajbi F; Peugniez C; Vernerey D; Meurisse A; Hammel P; Neuzillet C; Borg C; Turpin A
    Oncologist; 2020 Nov; 25(11):e1701-e1710. PubMed ID: 32886823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer.
    Wang ZQ; Zhang F; Deng T; Zhang L; Feng F; Wang FH; Wang W; Wang DS; Luo HY; Xu RH; Ba Y; Li YH
    Cancer Commun (Lond); 2019 May; 39(1):26. PubMed ID: 31068222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
    Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
    Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
    Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
    Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
    Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
    [No Abstract]   [Full Text] [Related]  

  • 11. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older.
    Mizrahi JD; Rogers JE; Hess KR; Wolff RA; Varadhachary GR; Javle MM; Shroff RT; Ho L; Fogelman DR; Raghav KPS; Overman MJ; Pant S
    Pancreatology; 2020 Apr; 20(3):501-504. PubMed ID: 31932214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study.
    Van Laethem JL; Borbath I; Prenen H; Geboes KP; Lambert A; Mitry E; Cassier PA; Blanc JF; Pilla L; Batlle JF; Garrote MR; Pazo-Cid RA; Gallego I; Smith KE; Ellmark P; Pico de Coaña Y; Ambarkhane SV; Macarulla T
    Lancet Oncol; 2024 Jul; 25(7):853-864. PubMed ID: 38834087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy.
    de Ortiz de Choudens S; Visotcky A; Banerjee A; Aldakkak M; Tsai S; Evans DB; Christians KK; Clarke CN; George B; Shreenivas A; Kamgar M; Chakrabarti S; Dua KS; Khan AH; Madhavan S; Erickson BA; Hall WA
    Cancer Med; 2024 Jan; 13(1):e6582. PubMed ID: 38140796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
    Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis.
    Rochefort P; Lardy-Cleaud A; Sarabi M; Desseigne F; Cattey-Javouhey A; de la Fouchardière C
    Oncologist; 2019 Dec; 24(12):1543-1548. PubMed ID: 31164454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.
    Cecchini M; Salem RR; Robert M; Czerniak S; Blaha O; Zelterman D; Rajaei M; Townsend JP; Cai G; Chowdhury S; Yugawa D; Tseng R; Mejia Arbelaez C; Jiao J; Shroyer K; Thumar J; Kortmansky J; Zaheer W; Fischbach N; Persico J; Stein S; Khan SA; Cha C; Billingsley KG; Kunstman JW; Johung KL; Wiess C; Muzumdar MD; Spickard E; Aushev VN; Laliotis G; Jurdi A; Liu MC; Escobar-Hoyos L; Lacy J
    JAMA Oncol; 2024 Aug; 10(8):1027-1035. PubMed ID: 38900452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Important Radiologic and Clinical Factors for Predicting Overall Survival in Pancreatic Adenocarcinoma Patients Who Underwent FOLFIRINOX.
    Park SJ; Kim JH; Choi SY; Joo I
    Pancreas; 2024 Aug; 53(7):e553-e559. PubMed ID: 38530942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
    Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
    Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy.
    Bullock A; Rowan CG; Oestreicher N; Yeganegi H; Chiorean EG
    J Manag Care Spec Pharm; 2020 Jul; 26(7):872-878. PubMed ID: 32584677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.